Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

@article{Khoury2021NeutralizingAL,
  title={Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.},
  author={David S. Khoury and Deborah Cromer and Arnold Reynaldi and Timothy E. Schlub and Adam K. Wheatley and Jennifer A. Juno and Kanta Subbarao and Stephen J. Kent and James A. Triccas and Miles P. Davenport},
  journal={Nature medicine},
  year={2021}
}
Predictive models of immune protection from COVID-19 are urgently needed to identify correlates of protection to assist in the future deployment of vaccines. To address this, we analyzed the relationship between in vitro neutralization levels and the observed protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using data from seven current vaccines and from convalescent cohorts. We estimated the neutralization level for 50% protection against detectable SARS… 

Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination

TLDR
Specific neutralizing activities were higher in infected than in vaccinated individuals, and no difference in the quality of these antibodies was observed between hospitalized and non-hospitalized patients, despite significantly lower titers in the latter group.

Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels

TLDR
This work demonstrates that appropriately calibrated neutralizing antibody measurements determined by a high throughput surrogate viral neutralization test can be used to provide a semi-quantitative estimate of protection against infection.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

TLDR
Correlates of protection can be used to bridge to new populations using validated assays and extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted.

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

TLDR
Data show that vaccine-induced antibodies in several patients with MM lack detectable virus-neutralizing activity, which has several implications for the emerging application of booster vaccines in immunocompromised hosts.

Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population

TLDR
There were significant differences observed in NAb titer after 180 days by age, sex, COVID-19 infection, tobacco use, and asthma patients, however, SARS-CoV-2 infection along with two dosages of immunization upheld N Ab titer even at the end of the study period.

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant

TLDR
The data indicate that antibodies neutralize the SARS-CoV-2 Delta variant 4 times less efficiently than they neutralize an earlier strain.

Immune response against SARS-CoV-2 variants: the role of neutralization assays

TLDR
Common neutralization assays based on infectious and pseudotyped viruses are described and their role in testing neutralizing responses against new SARS-CoV-2 variants are evaluated.

An immune correlate of SARS-CoV-2 infection and severity of reinfections

TLDR
Prior infection-induced immunity is protective against infection when predominantly gamma and delta SARS-CoV-2 circulated, and the protective antibody titers presented may be useful for vaccine policy and control measures.
...

References

SHOWING 1-10 OF 54 REFERENCES

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

TLDR
A role for potent neutralizing antibodies (nAbs) in prophylaxis, and potentially therapy, of COVID-19 is suggested, as indicated by maintained weight and low lung viral titers in treated animals, and the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters.

Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques

TLDR
It is demonstrated that relatively low antibody titers are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may also contribute to protection if antibody responses are suboptimal.

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

TLDR
The dynamics of memory responses to SARS-CoV-2 and the mechanisms of immune control are crucial for the rational design and deployment of vaccines and for understanding the possible future trajectories of the pandemic.

Evolution of antibody immunity to SARS-CoV-2.

TLDR
The humoral memory response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence, and the antibodies expressed have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response.

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

TLDR
It is indicated that SARS-CoV-2 immunity after infection might be transiently protective at a population level and might require greater immunogenicity and durability than natural infection to drive long-term protection.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

TLDR
Results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals, and assessing virus-specific immune memory over at least a 6-month period is likely necessary to ascertain the durability of immune memory to SARS-CoV-2.

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

TLDR
A selection of existing assays for measuring antibody-mediated virus neutralization and animal models of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are analyzed and a framework for comparing results between studies and reconciling observed differences in the effects of interventions is provided.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
...